[go: up one dir, main page]

WO2002040702A3 - Methods for the treatment of cancer and other diseases and methods of developing the same - Google Patents

Methods for the treatment of cancer and other diseases and methods of developing the same Download PDF

Info

Publication number
WO2002040702A3
WO2002040702A3 PCT/US2001/046194 US0146194W WO0240702A3 WO 2002040702 A3 WO2002040702 A3 WO 2002040702A3 US 0146194 W US0146194 W US 0146194W WO 0240702 A3 WO0240702 A3 WO 0240702A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diseases
treatment
developing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/046194
Other languages
French (fr)
Other versions
WO2002040702A2 (en
Inventor
Vladimir D Kravtsov
Mark J Koury
Mace Rothenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to AU2002239491A priority Critical patent/AU2002239491A1/en
Publication of WO2002040702A2 publication Critical patent/WO2002040702A2/en
Anticipated expiration legal-status Critical
Publication of WO2002040702A3 publication Critical patent/WO2002040702A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention relates to methods of determining drug combinations and administration protocols that can be used for the treatment of cancer and other diseases and conditions. The invention also relates to specific methods of treating diseases and conditions such as cancer, as well as to pharmaceutical compositions and kits that can be used in such methods.
PCT/US2001/046194 2000-11-09 2001-11-08 Methods for the treatment of cancer and other diseases and methods of developing the same Ceased WO2002040702A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002239491A AU2002239491A1 (en) 2000-11-09 2001-11-08 Methods for the treatment of cancer and other diseases and methods of developing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24671700P 2000-11-09 2000-11-09
US60/246,717 2000-11-09

Publications (2)

Publication Number Publication Date
WO2002040702A2 WO2002040702A2 (en) 2002-05-23
WO2002040702A3 true WO2002040702A3 (en) 2004-01-08

Family

ID=22931903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046194 Ceased WO2002040702A2 (en) 2000-11-09 2001-11-08 Methods for the treatment of cancer and other diseases and methods of developing the same

Country Status (2)

Country Link
AU (1) AU2002239491A1 (en)
WO (1) WO2002040702A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691646T3 (en) 2005-07-15 2018-11-28 Micell Technologies, Inc. Polymer coatings containing controlled morphology drug powder
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (en) 2007-01-08 2014-10-22 米歇尔技术公司 Stent with biodegradable layer
EA020655B1 (en) 2008-04-17 2014-12-30 Миселл Текнолоджиз, Инк. Stents having bioabsorbable layers
EP2411083A4 (en) 2009-03-23 2013-11-13 Micell Technologies Inc MEDICAL DEVICE FOR DELIVERY OF MEDICAMENT
CN102481195B (en) 2009-04-01 2015-03-25 米歇尔技术公司 coated stent
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
BR112012024619A2 (en) * 2010-03-31 2016-05-31 Diatech Oncology Llc system and method for evaluating anticancer drug candidate
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
WO2013172955A1 (en) * 2012-05-15 2013-11-21 Diatech Oncology Tumor cell isolation/purification process and methods for use thereof
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2912387C (en) 2013-05-15 2019-04-16 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2015171848A2 (en) * 2014-05-08 2015-11-12 Diatech Oncology, Llc Synergism and antagonism between multiple anti-cancer agents determined by mick assay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017177A1 (en) * 1993-01-27 1994-08-04 Batle Luminetrics Enterprises, Inc. Methods and kits for determining effects of anti-cancer agents on cancer cells
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017177A1 (en) * 1993-01-27 1994-08-04 Batle Luminetrics Enterprises, Inc. Methods and kits for determining effects of anti-cancer agents on cancer cells
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRAVTSOV V.D. ET AL.: "Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias.", BLOOD, vol. 92, no. 3, 1 August 1998 (1998-08-01), pages 968 - 980, XP002118802 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US9415142B2 (en) 2006-04-26 2016-08-16 Micell Technologies, Inc. Coatings containing multiple drugs
US11850333B2 (en) 2006-04-26 2023-12-26 Micell Medtech Inc. Coatings containing multiple drugs
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
US8900651B2 (en) 2007-05-25 2014-12-02 Micell Technologies, Inc. Polymer films for medical device coating
US9486431B2 (en) 2008-07-17 2016-11-08 Micell Technologies, Inc. Drug delivery medical device
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants

Also Published As

Publication number Publication date
WO2002040702A2 (en) 2002-05-23
AU2002239491A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
WO2003030934A3 (en) Cpg formulations and related methods
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
IL173348A (en) Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments
NO20053855L (en) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases.
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2004071382A3 (en) Substituted heterocycles
IS6558A (en) Mixed disease treatment with vasoconstrictor
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2007002836A3 (en) Methods and compositions for the prevention and treatment of kidney disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP